Skip to content

Psychedelic-assisted therapy: all studies

Page 173 of 294: studies 1,721 to 1,730 of 2,939, newest first. Back to the psychedelic-assisted therapy overview

Research

A reflection on paradigmatic tensions within the FDA advisory committee for MDMA-assisted therapy.

Journal of Psychopharmacology April 1, 2025 Leor Roseman 12 citations

The recent rejection of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy by the U.S. Food and Drug Administration (FDA) is a dramatic moment in the re-emergence of psychedelic research. In this perspective, I argue that it represents a case study for paradigmatic tensions within psychopharmacology. The regulatory system is still influenced by a paradigm that sees the therapeutic...

DOI: 10.1177/02698811241309611 (opens in new tab) Full text (opens in new tab) Set and setting Psychedelics hallucinogens Entheogens Psychedelic medicine +7

Social Workers' Attitudes and Beliefs about MDMA-Assisted Therapy for Adolescents with PTSD.

Social Work April 1, 2025 Maha N. Mian, Jordan Horan, Taweh Hunter et al. 1 citation

Given the widespread interest and ongoing study on MDMA-assisted therapy (MDMA-AT) for PTSD, its implications for unique populations-such as adolescents-require further understanding. Social workers will likely play a crucial role in the potential implementation of this intervention, but their perspectives remain unknown. The study includes 222 social workers randomized to read one of two...

Break on Through: Betty Eisner's Problematic Use of Psychedelics, Groups, and Control for Integrative Experiences.

Journal of the History of the Behavioral Sciences April 1, 2025 Tal Davidson, Patric Plesa 2 citations

Betty Eisner represents a prominent figure in the "golden age" of psychedelics research, as well as a cautionary tale about questionable therapeutic practices, exercising authority and control, and the misuse of psychedelics during the counterculture of the 1960s and 70s. Situating her work and the consequences of her problematic practices in the counterculture, the Human Potential Movement,...

DOI: 10.1002/jhbs.70027 (opens in new tab) Full text (opens in new tab) Group therapy Psychedelics Psychedelic‐assisted psychotherapy Hallucinogenic therapy +5

[Interventional psychiatric procedures and novel substances for the treatment of affective disorders: An overview and outlook].

Therapeutische Umschau April 1, 2025 Tobias Bracht, Daniela Hubl, Kristina Adorjan et al. 1 citation

Depression is one of the most common mental disorders. The effectiveness of pharmacological and psychotherapeutic treatments is well documented. Remission rates are around 67 % for pharmacological antidepressant initial and secondary treatment of a depressive episode in unipolar disorders. However, patients with a depressive episode who do not respond to at least two successive attempts at...

DOI: 10.23785/TU.2025.02.005 (opens in new tab) Full text (opens in new tab) Treatment-resistant depression Electroconvulsive therapy ect Ketamine/esketamine Depression therapy innovations +3

From Efficacy to Effectiveness: Evaluating Psychedelic Randomized Controlled Trials for Trustworthy Evidence‐Based Policy and Practice

Pharmacology Research & Perspectives April 1, 2025 Eduardo Ekman Schenberg 9 citations

ABSTRACT The recent review of a new drug application for MDMA‐assisted therapy for posttraumatic stress disorder by the United States' Food and Drug Administration (FDA) highlighted epistemological and methodological challenges for evidence assessments. Similar challenges will also be faced in reviews of other compounds in early‐ and late‐stage development, like psilocybin for depression. The...

DOI: 10.1002/prp2.70097 (opens in new tab) Randomized controlled trial Blinding Internal validity External validity +4

Effects of a single dose of psilocybin on diet-induced weight loss in obese mice

March 31, 2025 Ryan J. Keenan, Rezaul Haque, Xianbo Jin et al. preprint

Abstract Prolonged obesity induces enduring structural changes within neural circuits that contribute to maintaining the body at an elevated/obese body weight. These circuits regulate various mechanisms which can inhibit extreme or persistent weight loss. Therefore, a potential therapeutic strategy to facilitate weight loss is to promote structural plasticity within the brain. Psychedelic...

Utilizing Psychedelics to Enhance Well-Being: A Systematic Review

Journal of Psychoactive Drugs March 31, 2025 Samuel Thomson, Nikos Thomacos 11 citations

Psychedelic-assisted therapy is gaining recognition for its potential to enhance human functioning. While most research has focused on psychedelic' therapeutic use for mental illness, this review applies the PERMA Theory of Well-Being to systematically examine their role in enhancing well-being in healthy individuals. The final search of five academic databases was conducted on February 4,...

Metacognitive Feelings of Epistemic Gain are Central to the Understanding of Psychedelic-Induced Mystical-Type Experiences

Cognitive Therapy and Research March 29, 2025 Federico Seragnoli, Fabienne Picard, Gabriel Thorens et al. 4 citations

Abstract Purpose Despite the presence of mystical-type experiences in psychedelic-assisted therapy (PAT), an understanding of the cognitive processes involved is still lacking. Guided by theory and empirical research, we hypothesized a cognitive-grounded perspective based on current metacognition models to promote the understanding of the psychological processes involved in mystical-type...

DOI: 10.1007/s10608-025-10588-z (opens in new tab) Mysticism Metacognition Feeling Cognitive psychology +2

Clinical Research on Lysergic Acid Diethylamide (LSD) in Psychiatry and Neuroscience.

Pharmaceuticals March 29, 2025 Hossein Omidian, Alborz Omidian 5 citations

Lysergic acid diethylamide (LSD) is gaining renewed interest as a potential treatment for anxiety, depression, and alcohol use disorder, with clinical trials reporting significant symptom reductions and long-lasting effects. LSD modulates serotonin (5-HT2A) receptors, which, in turn, influence dysfunctional brain networks involved in emotional processing and cognition. It has also shown promise...

DOI: 10.3390/ph18040499 (opens in new tab) Full text (opens in new tab) LSD Clinical research Pharmacogenetics Serotonin receptors +8

Ayahuasca in the treatment of the consequences of chronic childhood sexual abuse in a religious community

March 27, 2025 Mika Turkia preprint

This retrospective case study features a woman in her mid-50s who spent her childhood in a religious community plagued by sexual abuse of children. She was abused by her father for more than a decade. The church and her mother ignored her reports about it. In her early twenties, she enrolled herself in the Erhard Seminars Training program that destabilized her, inducing a first-onset psychosis,...

DOI: 10.31234/osf.io/mzkyv_v1 (opens in new tab) Ayahuasca Sexual abuse Psychotherapist Clinical psychology +3